Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03788811 · ClinicalTrials.gov registry record
ERG Components in Schizophrenia and Bipolar Disorder Type I
A clinical trial of Schizophrenia and Bipolar I Disorder, sponsored by diaMentis.
- Active
- Registry status
- 300
- Enrollment target
- 19
- Study locations
NCT03788811: Active study of Schizophrenia and Bipolar I Disorder, sponsored by diaMentis.
NCT03788811 is a study of Schizophrenia and Bipolar I Disorder that is active but no longer recruiting, run by diaMentis. The registered enrollment target is 300 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (38% higher). The trial reports 19 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03788811, a study of Schizophrenia and Bipolar I Disorder, is active but no longer recruiting, sponsored by diaMentis.
- ACTIVE NOT RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 19
- Study locations
Study Summary
This study will further assess ERG components obtained with different ERG devices, to be considered in a prediction model for each diagnosis. The prediction models are diaMentis proprietary software used as an ERG-based diagnostic test (classified as a Software as Medical Device, SaMD) to support the diagnosis of schizophrenia and bipolar disorder type I. They involve the processing and analysis of specific retinal biosignatures (RSPA) with the support of statistical and mathematical modelling processes e.g. machine learning and statistical learning.
Primary Outcome
ERG components are retinal signal features (signal amplitude vs time) in the electrical signal recorded up to 100 msec post stimulation.
Conditions Studied
Interventions
- DEVICE ERG assessment (RSPA)
Study Locations (19)
California
- Collaborative Neuroscience Research LLC - Garden Grove
- Synergy San Diego - Lemon Grove
- Collaborative Neuroscience Research LLC - Torrance
New York
- The Zucker Hillside Hospital - Glen Oaks
- University of Rochester Medical Center - Rochester
- Richmond Behavioral Associates - Staten Island
Victoria
- Monash Medical Centre - Clayton
- Barwon Health University Hospital - Geelong
- Albert Road Clinic - Melbourne
Quebec
- Institut Universitaire en Santé Mentale de Montréal - Montreal
- Douglas Mental Health University Institute - Montreal
- CISSS-CA Hôpital de Saint-Georges - Saint-Georges
Florida
- Segal trials West Broward Outpatient Site - Lauderhill
- Segal Trials Miami Lakes Medical Research - Miami Lakes
Ontario
- Queen's University - Kingston
- Centre for Addiction and Mental Health (CAMH) - Toronto
Massachusetts
- McLean Hospital - Belmont
New Jersey
- Rutgers University Behavioral HealthCare - Piscataway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2018-07-05 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT03788811 still lists
NCT03788811 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (38% higher).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which ERG assessment (RSPA) is the first listed.
NCT03788811 lists 19 locations in 9 states (California, New York, Victoria).
Frequently Asked Questions
What is clinical trial NCT03788811 about?
NCT03788811 is a clinical study titled "ERG Components in Schizophrenia and Bipolar Disorder Type I". This study will further assess ERG components obtained with different ERG devices, to be considered in a prediction model for each diagnosis. The prediction models are diaMentis proprietary software used as an ERG-based diagnostic test (classified as a Software as Medical Device, SaMD) to support th...
What is the current status of trial NCT03788811?
This trial is currently active not recruiting. The enrollment target is 300 participants. The study started on 2018-07-05. Estimated completion is 2026-12-31.
What conditions does trial NCT03788811 study?
This clinical trial studies the following conditions: Schizophrenia, Bipolar I Disorder.
What interventions are being tested in trial NCT03788811?
The interventions under investigation include: ERG assessment (RSPA) (DEVICE).
Who is sponsoring clinical trial NCT03788811?
This trial is sponsored by diaMentis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03788811 being conducted?
This trial has 19 study locations across California, Florida, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03788811's enrollment target sits among peer trials
300 57th of 315 higher than 255 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI